Protalix Biotherapeutics (PLX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2023 | 06-2023 | 03-2023 | 12-2022 | 09-2022 | |
| Sales | 10,345 | 35,075 | 9,588 | 8,617 | 14,183 |
| Cost of Goods | 4,893 | 6,148 | 3,085 | 2,397 | 7,074 |
| Gross Profit | 5,452 | 28,927 | 6,503 | 6,220 | 7,109 |
| Operating Expenses | 8,232 | 8,654 | 9,047 | 9,112 | 10,308 |
| Operating Income | -1,887 | 20,421 | -2,459 | -2,495 | -3,125 |
| Other Income | 168 | -774 | -477 | -715 | -442 |
| Pre-tax Income | -1,719 | 19,647 | -2,936 | -3,210 | -3,567 |
| Income Tax | 133 | 308 | 195 | N/A | N/A |
| Net Income Continuous | -1,852 | 19,339 | -3,131 | -3,740 | -3,567 |
| Net Income | $-1,852 | $19,339 | $-3,131 | $-3,740 | $-3,567 |
| EPS Basic Total Ops | -0.03 | 0.29 | -0.05 | -0.08 | -0.07 |
| EPS Basic Continuous Ops | -0.03 | 0.29 | -0.05 | -0.07 | -0.07 |
| EPS Diluted Total Ops | -0.04 | 0.21 | -0.05 | -0.08 | -0.07 |
| EPS Diluted Continuous Ops | -0.02 | 0.23 | -0.05 | -0.07 | -0.07 |
| EBITDA(a) | $-1,522 | $20,782 | $-2,099 | $-2,144 | $-2,774 |